Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Key Points

• To evaluate the perceived benefits of sublingual immunotherapy (NPP-SLIT) in patients with allergic rhinitis and asthma.
• Conducted a real-world cohort study involving patients undergoing sublingual immunotherapy.
• Collected data on patient-reported benefits and expectations over time.
• Analyzed findings to connect patient expectations with clinical outcomes.
• Patients reported sustained and clinically meaningful benefits from NPP-SLIT.
• The findings support the use of patient-reported benefits as a valuable endpoint in allergy treatments.